BRAND NAME / COMPANY / REIMBURSEMENT AND LOGISTICS PROGRAM (APPROVED BY HEALTH CANADA FOR IBD INDICATIONS)

Zeposia®/Bristol Myers Squibb/Bristol Myers Squibb Access Support® (2022)

 

APPROVED CLINICAL INDICATIONS

(may vary within provinces – refer to local patient support program)

Ulcerative colitis

CLASS

Sphingosine 1 phosphate (S1P) modulator

ACTION

Binds with high affinity to S1P receptor 1 and reduces the capacity of lymphocytes to migrate from lymphoid tissue, reducing the number of circulating lymphocytes in peripheral blood and lymphocyte migration into the intestines. Decreases the cells involved in immune response.